AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00002110
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05836506
Drug: ABBV-903 Tablet Form 1
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets
Trial: NCT05836506
Drug: ABBV-903 Tablet Form 2
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets
Trial: NCT05753943
Drug: QUALI
RxNorm normalized name: dequalinium
DrugBank: Quisqualic acid (DB02999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication 1 pill at night
Trial: NCT05993858
Drug: 3cycles (Toripalimab + cetuximab)
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab by intravenous (IV) infusion every 3 weeks (Q3W), 3 preoperative and 17 consolidated doses.~The preoperative starting dose of cetuximab is 400 mg/m\^2 by IV infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 9.
Trial: NCT00004854
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05751187
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed was given as 500 mg/m\^2 via intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle for 4-6 cycles.
Trial: NCT05751187
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin was given as 75 mg/m\^2 via intravenous (IV) infusion (administered approximately 30 minutes after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
Trial: NCT06463132
Drug: PEP
RxNorm normalized name: PEPAP
DrugBank: 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (DB01562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEP (Purified Exosome Product)
Trial: NCT05751187
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin was given as Aare Under the Curve (AUC) 5 (5 mg/mL/min; over 15-60 min) via intravenous (IV) infusion (administered immediately after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
Trial: NCT05751187
Drug: Dexamethasone 4 mg
RxNorm normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, the day of, and the day after pemetrexed administration.
Trial: NCT04264806
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.
Trial: NCT04264806
Drug: Cusatuzumab
RxNorm normalized name: Cusatuzumab
DrugBank: Cusatuzumab (DB15100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
Trial: NCT06243536
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide will be administered through 12 weeks.
Trial: NCT04885998
Drug: Tarlatamab
RxNorm normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarlatamab will be administered as an intravenous (IV) infusion.
Trial: NCT04885998
Drug: AMG 404
RxNorm normalized name: Anti-pd-1 monoclonal antibody amg 404
DrugBank: AMG 424 (DB17357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 404 will be administered as an intravenous (IV) infusion.
Trial: NCT06554795
Drug: DB-1419
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered Injection of Vein (I.V.)
Trial: NCT06061926
Drug: Celery Seed
RxNorm normalized name: CELERY SEED
DrugBank: Celery (DB10517)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celery seed capsules (Apium graveolens L.) 150 mg twice times at day, one capsule with 75 mg before breakfast and one capsule with 75 mg before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
Trial: NCT04792645
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cognition-enhancing medication
Trial: NCT05969496
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib is a potent oral, vascular endothelial growth factor, c-kit and platelet derived growth factor inhibitor.
Trial: NCT05969496
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a type of immunotherapy. It stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
Trial: NCT06592339
Drug: MK-0616
RxNorm normalized name: vitamin MK 7
DrugBank: Vitamin K7 (DB15664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT06588517
Drug: Pirfenidone Modified-Release Tablets
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: take the tablet under fed condition, 1 tablet at a time, once a day.
Trial: NCT06588517
Drug: Pirfenidone Tablets
RxNorm normalized name: Pirfenidone Tablets
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ake the tablet under fed condition, 1 tablet at a time, three times a day.
Trial: NCT06590259
Drug: Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab
RxNorm normalized name: edaravone
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Systemic therapy including PD-1 inhibitor starts on the 7th day after ablation (sintilimab 200 mg IV D1 + mFOLFOX6 or FOLFIRI + bevacizumab or cetuximab (determined according to the subject's first-line chemotherapy regimen), Q3W, chemotherapy for 4-6 cycles. Sintilimab continues until disease progression, not exceeding a maximum of 2 years.）
Trial: NCT06039449
Drug: VYD222 (pemivibart)
RxNorm normalized name: PEMIVIBART
DrugBank: Pemivibart (DB18720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.
Trial: NCT06654635
Drug: Rhomboid intercostal plane block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in this group will receive ultrasound -guided rhomboid intercostal plane block after induction of general anesthesia. The rhomboid intercostal block will be performed at the T6 levels, bilaterally.
Trial: NCT06389955
Drug: TP 3654
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TP 3654 is an investigational orally delivered drug
Trial: NCT05584007
Drug: Flucloxacillin Only Product in Oral Dose Form
RxNorm normalized name: Flucloxacillin only product in oral dose form
DrugBank: Flucloxacillin (DB00301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment
Trial: NCT05180773
Drug: Bromocriptine
RxNorm normalized name: Bromocriptine
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.
Trial: NCT06591845
Drug: Ziresovir 125 mg
RxNorm normalized name: Ziresovir
DrugBank: Ziresovir (DB15145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
Trial: NCT06591845
Drug: Ziresovir 500 mg
RxNorm normalized name: Ziresovir
DrugBank: Ziresovir (DB15145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
Trial: NCT06591845
Drug: Moxifloxacin hydrochloride tablet 400 mg
RxNorm normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Substance: Moxifloxacin hydrochloride Pharmaceutical Form: Tablet Route of Administration: Oral
Trial: NCT06604351
Drug: Sintilimab, Nab-Paclitaxel, and Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cryoablation received at least 2 or more depending on the mass, with 2-3 cycles；Sintilimab 200 mg Q3W plus Nab-Paclitaxel 260mg / m2(Day 1) Q3W + carboplatin AUC 4.25 or 5 (Day 1) Q3W, 4 cycles，until 24 months
Trial: NCT06596161
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receving iron
Trial: NCT05733351
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05733351
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05733351
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05733351
Drug: Vudalimab
RxNorm normalized name: Vudalimab
DrugBank: Vudalimab (DB18833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05978167
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 20 mg Methylphenidate
Trial: NCT05823480
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT05482971
Drug: Ropeginterferon alfa-2b-njft (P1101)
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ropeginterferon alfa-2b-njft (P1101)
Trial: NCT04188639
Drug: Emicizumab Injection
RxNorm normalized name: emicizumab Injection
DrugBank: Emicizumab (DB13923)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks follow-up with Immunosuppressive therapy (IST) at the investigators discretion.
Trial: NCT00266617
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06585852
Drug: RGD
RxNorm normalized name: Delta24-RGD
DrugBank: Tasadenoturev (DB17178)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group main material
Trial: NCT06590298
Drug: Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The intervention group will be added 5 mg of aripiprazole as an adjunct with the usual antipsychotic treatment to the females on antipsychotic treatment
Trial: NCT05710367
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Forxiga® as an add-on treatment in patients with renal and/or cardiac association FD in an exploratory framework.
Trial: NCT04815876
Drug: Antibiotic (prophylaxis)
RxNorm normalized name: STONE PROPHYLAXIS
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy.
Trial: NCT05180773
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.
Trial: NCT05375942
Drug: Inflectra
RxNorm normalized name: Inflectra
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. To describe the characteristics of patients newly initiated on Inflectra.
Trial: NCT05375942
Drug: Inflectra
RxNorm normalized name: Inflectra
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2. To describe 6-month outcomes after initiating Inflectra, among patients who have 6 months follow-up information in the CorEvitas' RA Registry.
Trial: NCT02404896
Drug: Metreleptin
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin open-label treatment
Trial: NCT06033352
Drug: Ivermectin 1% cream
RxNorm normalized name: IVERMECTIN 1% CREAM,TOP
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of ivermectin 1% cream 1x/day. Interruption for 4 days in case of irritation/redness.
Trial: NCT05322681
Drug: Pregabalin 150mg
RxNorm normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
Trial: NCT05813600
Drug: Nirmatrelvir/Ritonavir
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature \>38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days, and the control group not given any antiviral drugs.
Trial: NCT05642403
Drug: XW001
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inhaled XW001
Trial: NCT05869188
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Evaluate serum irisin level in acne vulgaris and compare it with healthy control .~* Evaluate the effect of systemic isotretinoin on serum irisin in acne vulgaris patients .
Trial: NCT04891068
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5-Azacitidine is a pyrimidine nucleoside analog in which nitrogen replaces carbon at position 5
Trial: NCT05797467
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Targeted therapy regimens are recommended based on gene testing results. For colorectal cancer patients with KRAS/NRAS/BRAF gene mutations, it is recommended to use Bevacizumab in combination with chemotherapy. For right-sided colon cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Bevacizumab. For left-sided colon and rectal cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Cetuximab.When using targeted therapy in combination with chemotherapy, the treatment course should be synchronized with chemotherapy (Bev 5mg/kg iv d1 or Cet 500mg/m2 iv d1).
Trial: NCT05663749
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000mg for 8 weeks
Trial: NCT05663749
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg for 8 weeks
Trial: NCT05287165
Drug: IM96 CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
Trial: NCT05609656
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months~Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor).
Trial: NCT05468996
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
Trial: NCT05738642
Drug: 4 factor Prothrombin Complex Concentrates
RxNorm normalized name: Prothrombin complex concentrate
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster 4 f - PCC by intravenous infusion (boya 4 f - PCC, a bottle of 400 IU) : 25 IU/kg dose infusion time: as soon as possible after admission infusion, at the latest within 2 hours after admission to infusion infusion method: Sodium chloride injection 5% glucose injection was diluted into 50 ml per bottle, and then intravenous infusion was carried out with a blood transfusion device with a mesh device. The infusion was finished in 60-120 minutes
Trial: NCT06561048
Drug: Soquelitinib
RxNorm normalized name: Soquelitinib
DrugBank: Soquelitinib (DB18749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soquelitinib 200 mg tablets will be taken by mouth two times a day
Trial: NCT06561048
Drug: Belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle
Trial: NCT06561048
Drug: Pralatrexate
RxNorm normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle
Trial: NCT06236269
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle
Trial: NCT05843643
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Tablets
Trial: NCT04682366
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral drug: 10 days of 0.4 mg of oral Tamsulosin
Trial: NCT05338619
Drug: Lazertinib
RxNorm normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Trial: NCT05153096
Drug: NBL-015
RxNorm normalized name: NBL-015
DrugBank: NBL-015 (DB18183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBL-015 by intravenous infusion
Trial: NCT04098718
Drug: Benralizumab
RxNorm normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg sub cut once only
Trial: NCT00000715
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000715
Drug: Sulfamethoxazole-Trimethoprim
RxNorm normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06516978
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT06516978
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT06516978
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT06516978
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Trial: NCT06516978
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
Trial: NCT06516978
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax PO will be administered as per the schedule specified in the respective arm.
Trial: NCT06516978
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Chidamide PO will be administered as per the schedule specified in the respective arm.
Trial: NCT06516978
Drug: Penpulimab
RxNorm normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penpulimab IV infusion will be administered as per the schedule specified in the respective arm.